Trial Profile

A Randomized, Double-blind, Placebo-controlled, Phase 2b Trial With an Open-label Extension to Determine the Safety and Efficacy of GH001 in Patients With Treatment-resistant Depression

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs 5 Methoxy N N Dimethyltryptamine (Primary)
Indications Depression; Major depressive disorder
Focus Therapeutic Use
Sponsors GH Research

Most Recent Events

31 May 2025 Status changed from active, no longer recruiting to completed.
15 May 2025 According to a GH Research media release, company announces acceptance of poster has been accepted presenting data at the American Society of Clinical Psychopharmacology Annual Meeting (ASCP) in Arizona, United States from May 27 - 30.
14 May 2025 According to ATAI Life Sciences media release, company to report topline results in mid-year 2025

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com